Related Experiment Video
Updated: Sep 27, 2026

Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection
Published on: November 22, 2013
Development and mechanism of fluoroquinolone resistance in Legionella pneumophila
Daniel Jonas1, Inge Engels, Doris Hartung
1Institute of Environmental Medicine and Hospital of Epidemiology, University Hospital of Freiburg, Hugstetter Strasse 55, D-79106 Freiburg. djonas@IUK3.UKL.uni-Freiburg.de
Abstract:
The potential for selection in vitro of Legionella pneumophila mutants resistant to fluoroquinolones was investigated. Six distinct clinical isolates of L. pneumophila were subcultured in subinhibitory concentrations of ciprofloxacin, levofloxacin, clinafloxacin, trovafloxacin and moxifloxacin until MICs increased at least eight-fold. The numbers of serial passages required in microbroth dilution series were determined. The gyrA gene of the six parental strains, and 12 selected mutant strains, was sequenced. The five quinolones differed markedly in their ability to select mutants with decreased susceptibility. The average number of serial passages required was low in the cases of clinafloxacin (n = 10.6), ciprofloxacin and levofloxacin (both n = 13), but notably higher for trovafloxacin (n = 26.6) and moxifloxacin (n = 22.5). Five mutants treated with ciprofloxacin and three treated with moxifloxacin showed Thr83-->Lys or Thr83-->Ile amino acid changes in the gyrA gene. In conclusion, different quinolones lose their antimicrobial effect after a varying number of passages. This study demonstrated, for the first time to our knowledge, that gyrA in L. pneumophila is a possible target of fluoroquinolones.
Insights
Investigating fluoroquinolone resistance in Legionella pneumophila revealed that different antibiotics vary in their ability to select for resistant mutants. The gyrA gene was identified as a potential target for fluoroquinolone action in this bacterium.
Area of Science:
- Microbiology
- Molecular Biology
- Pharmacology
Background:
- Legionella pneumophila is a significant human pathogen.
- Fluoroquinolones are critical antibiotics for treating Legionella infections.
- Understanding resistance mechanisms is crucial for effective treatment.
Purpose of the Study:
- To investigate the in vitro selection of Legionella pneumophila mutants resistant to various fluoroquinolones.
- To determine the relative efficiency of different fluoroquinolones in selecting for resistance.
- To identify potential genetic targets associated with fluoroquinolone resistance.
Main Methods:
- Subculturing six clinical isolates of L. pneumophila in subinhibitory concentrations of five fluoroquinolones (ciprofloxacin, levofloxacin, clinafloxacin, trovafloxacin, moxifloxacin).
- Determining minimum inhibitory concentrations (MICs) and the number of serial passages required for resistance development.
- Sequencing the gyrA gene of parental and mutant strains.
Main Results:
- Fluoroquinolones exhibited marked differences in their ability to select for resistant L. pneumophila mutants.
- Fewer passages were required for resistance selection with clinafloxacin, ciprofloxacin, and levofloxacin compared to trovafloxacin and moxifloxacin.
- Amino acid changes (Thr83 to Lys or Ile) in the gyrA gene were observed in mutants selected by ciprofloxacin and moxifloxacin.
Conclusions:
- Different fluoroquinolones have varying efficacy in selecting for resistant Legionella pneumophila.
- The gyrA gene in L. pneumophila is a likely target for fluoroquinolone activity.
- These findings have implications for antibiotic stewardship and the development of new anti-Legionella therapies.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing
Clinical Significance of Antibiotic Resistance

